Rubius_Logo.jpg
Rubius Therapeutics Added to Nasdaq Biotechnology Index
December 17, 2018 16:05 ET | Rubius Therapeutics
CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, today...
Rubius_Logo.jpg
Rubius Therapeutics to Present at Evercore ISI HealthCONx Conference
November 19, 2018 16:05 ET | Rubius Therapeutics
CAMBRIDGE, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, announced...
Rubius_Logo.jpg
Rubius Therapeutics Reports Third Quarter 2018 Financial Results and Operational Progress
November 13, 2018 08:00 ET | Rubius Therapeutics
On Track to Submit First IND for RTX-134 in Q1 2019 CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company developing an entirely new...
Rubius_Logo.jpg
Rubius Therapeutics to Participate in Jefferies London Healthcare Conference
November 06, 2018 16:05 ET | Rubius Therapeutics
CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY),  a biotechnology company developing an entirely new class of allogeneic cellular therapies, announced...
Rubius_Logo.jpg
Rubius Therapeutics to Announce Third Quarter 2018 Financial Results
November 05, 2018 16:05 ET | Rubius Therapeutics
CAMBRIDGE, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, plans to...
Rubius_Logo.jpg
Rubius Therapeutics to Participate in the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
September 20, 2018 16:05 ET | Rubius Therapeutics
CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies,...
Rubius_Logo.jpg
Rubius Therapeutics Added to Russell 2000 and 3000 Indexes
September 14, 2018 16:05 ET | Rubius Therapeutics
CAMBRIDGE, Mass., Sept. 14, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies,...
Rubius_Logo.jpg
Rubius Therapeutics to Participate in the Morgan Stanley 16th Annual Global Healthcare Conference
September 04, 2018 16:05 ET | Rubius Therapeutics
CAMBRIDGE, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies,...
Rubius_Logo.jpg
Rubius Therapeutics Reports Second Quarter 2018 Financial Results
August 31, 2018 08:00 ET | Rubius Therapeutics
CAMBRIDGE, Mass., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies,...
Rubius_Logo.jpg
Rubius Therapeutics to Announce Second Quarter 2018 Financial Results
August 21, 2018 16:05 ET | Rubius Therapeutics
CAMBRIDGE, Mass., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies,...